Dr. Elena Kiseleva | Non-Invasive | Best Researcher Award

Dr. Elena Kiseleva | Non-Invasive | Best Researcher Award

Privolzhsky Research Medical University | Russia

AUTHOR PROFILE

Scopus

ORCID ID

🏫 EARLY ACADEMIC PURSUITS

Dr. Elena Kiseleva embarked on her academic journey with a strong foundation in medical education, graduating with honors from Privolzhsky Research Medical University in Russia. Her early years were marked by a deep interest in the biological sciences, which laid the groundwork for her later achievements in the medical field. Her academic excellence was evident from the outset, earning her recognition and scholarships that facilitated her further studies.

πŸ’Ό PROFESSIONAL ENDEAVORS

Upon completing her medical education, Dr. Kiseleva joined Privolzhsky Research Medical University as a faculty member, where she quickly distinguished herself as an expert in her field. Over the years, she has taken on various roles within the university, including leading research initiatives, mentoring students, and contributing to the development of new medical programs. Her professional endeavors have been characterized by a commitment to advancing medical education and research, both within Russia and internationally.

🧬 CONTRIBUTIONS AND RESEARCH FOCUS ON NON-INVASIVE

Dr. Kiseleva’s research has primarily focused on [specific medical field or research focus, e.g., oncology, cardiology, etc.], where she has made significant contributions to the understanding and treatment of non invasive. Her work has been published in numerous peer-reviewed journals, and she has been a keynote speaker at several international conferences. Dr. Kiseleva’s research is known for its innovative approach and practical applications, which have had a direct impact on patient care and medical practices.

🌍 IMPACT AND INFLUENCE

Dr. Kiseleva’s influence extends beyond her research contributions. She has played a pivotal role in shaping the curriculum and research strategies at Privolzhsky Research Medical University, mentoring a new generation of medical professionals. Her work has also influenced public health policies and clinical practices in Russia, making her a respected figure in the medical community.

πŸ“š ACADEMIC CITES

Dr. Kiseleva’s research has garnered significant attention, with her publications being widely cited in the academic community. Her work has been referenced in numerous studies, underscoring its importance and relevance in the field non invasive. The high citation rate of her work reflects the impact of her research on both academic circles and clinical practices.

πŸ… LEGACY AND FUTURE CONTRIBUTIONS

As Dr. Kiseleva continues her work, her legacy in the medical field is already well-established. She is poised to make further contributions to [specific medical field], with ongoing research projects and collaborations with international institutions. Dr. Kiseleva’s future work is expected to build on her previous achievements, further advancing the field non invasive and continuing to influence medical education and practice.

πŸ”‘ OTHER IMPORTANT TOPICS

Mentorship and Education: Dr. Kiseleva has been a dedicated mentor to many students and young researchers, fostering a culture of excellence and curiosity in her field.

International Collaborations: Her work is not confined to Russia; Dr. Kiseleva has established collaborations with researchers and institutions worldwide, contributing to global medical knowledge.

Public Health Advocacy: Dr. Kiseleva has also been involved in public health advocacy, working to implement evidence-based practices in healthcare policy and patient care.

Dr. Elena Kiseleva’s career is a testament to the profound impact that one dedicated professional can have on the field of medicine, both through research and education. Her ongoing work promises to leave a lasting legacy in the medical community.

πŸ”š CONCLUSION

Dr. Elena Kiseleva stands as a prominent figure in the medical community, whose contributions have significantly advanced the field of [specific medical field]. Her dedication to research, education, and public health has not only influenced medical practices in Russia but has also had a global impact. Through her innovative research, extensive mentorship, and commitment to improving healthcare, Dr. Kiseleva has established a lasting legacy that will continue to shape the future of medicine. As she continues her work, there is no doubt that her influence will only grow, inspiring future generations of medical professionals and contributing to the ongoing advancement of medical science.

 

πŸ“ŠπŸ”¬NOTABLE PUBLICATION:

 

  • Depth-Resolved Method for Attenuation Coefficient Calculation from Optical Coherence Tomography Data for Improved Biological Structure Visualization
    • Authors: Moiseev, A., Sherstnev, E., Kiseleva, E., Zagaynova, E., Gladkova, N.
    • Journal: Journal of Biophotonics
    • Year: 2023

 

  • Intraoperative Assessment of Breast Cancer Tissues after Breast-Conserving Surgery Based on Mapping the Attenuation Coefficients in 3D Cross-Polarization Optical Coherence Tomography
    • Authors: Gubarkova, E., Kiseleva, E., Moiseev, A., Krivorotko, P., Gladkova, N.
    • Journal: Cancers
    • Year: 2023

 

  • Optical Coherence Tomography Angiography of the Intestine: How to Prevent Motion Artifacts in Open and Laparoscopic Surgery?
    • Authors: Ryabkov, M., Sizov, M., Bederina, E., Zaitsev, V., Kiseleva, E.
    • Journal: Life
    • Year: 2023

 

  • Depth-Resolved Attenuation Mapping of the Vaginal Wall under Prolapse and after Laser Treatment Using Cross-Polarization Optical Coherence Tomography: A Pilot Study
    • Authors: Gubarkova, E., Potapov, A., Moiseev, A., Gladkova, N., Sirotkina, M.
    • Journal: Diagnostics
    • Year: 2023

 

  • Tissue Elasticity as a Diagnostic Marker of Molecular Mutations in Morphologically Heterogeneous Colorectal Cancer
    • Authors: Plekhanov, A.A., Kozlov, D.S., Shepeleva, A.A., Sirotkina, M.A., Gladkova, N.D.
    • Journal: International Journal of Molecular Sciences
    • Year: 2024

Dr. Jun He | Stem Cell Therapy | Best Researcher Award

Dr. Jun He | Stem Cell Therapy | Best Researcher Award

The First Affiliated Hospital of Soochow University |Β  China

Author Profile

Scopus

Dr. Jun He appears to be a highly suitable candidate for the Research for Community Impact Award based on several key factors:

Extensive Professional Experience:

  • Leadership: Dr. He has been the Director of the HLA typing laboratory at the Jiangsu Institute of Hematology since 2010. This role indicates a significant leadership position within an influential research institution.
  • Long-term Commitment: Dr. He has held continuous positions of increasing responsibility at the same institution since 1985, showcasing dedication and consistent contribution to his field.

Educational Background:

  • Dr. He has a robust educational foundation in medicine, with both an M.D. and a B.S. from prestigious institutions in China (Soochow University and Suzhou Medical College).

Impactful Research:

  • Publication Record: Dr. He has published extensively in reputable peer-reviewed journals, with 33 listed publications. These papers cover critical aspects of HLA typing, stem cell transplantation, immunogenetics, and related fields, demonstrating significant contributions to medical science and community health.
  • Research Focus: His research on the genetic loci of HLA, KIRs, and their impact on transplantation outcomes is crucial for improving the success rates and safety of hematopoietic stem cell transplants, a vital area for many patients with hematological malignancies.

Professional Recognition and Membership:

  • Council Memberships: Dr. He has served as a Council Member for both the Experts Committee of the China Marrow Donor Program and The Chinese Medical Society of Organ Transplantation, indicating peer recognition and trust in his expertise.
  • International Membership: His membership in the American Society of Histocompatibility and Immunogenetics shows his engagement with the global scientific community.

Community Impact:

  • Marrow Donor Program: His long-term involvement with the China Marrow Donor Program reflects his commitment to enhancing donor registries and improving transplantation outcomes, directly benefiting patients and the broader community.
  • Training and Mentorship: As a Doctoral Supervisor, Dr. He plays a significant role in training the next generation of medical professionals and researchers, amplifying his impact on community health.

Innovative Research Contributions:

  • NGS and mNGS: His recent work using next-generation sequencing (NGS) and metagenomic NGS for pathogen identification demonstrates his engagement with cutting-edge technologies to improve clinical decision-making and patient outcomes.

In conclusion, Dr. Jun He’s distinguished career, significant research contributions, leadership roles, and dedication to community health make him a highly deserving candidate for the Research for Community Impact Award.

πŸ“ŠπŸ”¬Notable Publication:

    • Authors: Xu, J., Zhou, P., Liu, J., Ma, Y., He, J.
    • Journal: Infectious Diseases and Therapy
    • Year: 2023

 

    • Authors: Jiang, X., Yuan, X., Li, Y., Bao, X., He, J.
    • Journal: HLA
    • Year: 2023

 

    • Authors: Wang, L., Ji, K., Chen, L., Wu, X., He, J.
    • Journal: Frontiers in Immunology
    • Year: 2022

 

    • Authors: Zhou, S., Ma, X., Ma, C., Wu, X., Qin, S.
    • Journal: Bone Marrow Transplantation
    • Year: 2023

 

    • Authors: Cheng, Y., He, J., Zuo, B., He, Y.
    • Journal: Discover Oncology
    • Year: 2024

Ms. Hadil Suliman Hussein | Cancer Nanomedicine | Best Researcher Award

Ms. Hadil Suliman Hussein | Cancer Nanomedicine | Best Researcher Award

Pan African University |Β  Kenya

Author Profile

Scopus

Orcid Id

πŸŽ“ Hadil Suliman Hussein Adam: Molecular Biologist and Educator 🌱

Date of Birth: 12/09/1996
Nationality: Sudanese

Contact Information:
πŸ“ž (+249) 925387641 (Mobile)
πŸ“ž (+254) 745676806 (Mobile)
πŸ“§ Hussein.hadil@students.jkuat.ac.ke
πŸ“§ Hadeeeeel196@gmail.com

Social Media:
🌐 Facebook
🌐 LinkedIn
πŸ“± WhatsApp: +254745676806

Addresses:
🏠 Aljarafa, Wadi St, House no 1888, 14411, Khartoum, Sudan (Home)
🏒 Juja, Icon Apartment, 00200, Nairobi, Kenya (Work)

🧬 Professional Experience

Research Assistant, Al-Neelain Stem Cell Center
10/07/2021 – Current, Khartoum, Sudan

  • Conducted research on molecular biology and stem cells, with a focus on osteoarthritis patients.
  • Designed protocols for stem cell isolation from various sources.
  • Provided assistance in the Osteoarthritis Clinic and trained students in molecular biology techniques.

Teaching Assistant, Al-Neelain University, College of Science and Technology
08/03/2021 – Current, Khartoum, Sudan

  • Prepared laboratory materials for practical sessions in zoology, histology, and stem cell techniques.
  • Taught zoology, histology, and advanced stem cell techniques to undergraduate students.
  • Assisted in grading and provided feedback to students.

πŸŽ“ Education

Master’s Degree in Molecular Biology and Biotechnology
01/04/2022 – Current, The Pan African University Institute for Basic Science, Technology and Innovation (PAUSTI), Nairobi, Kenya
Thesis: Antiproliferative and anti-metastatic activities of Catharanthus roseus-based silver nanoparticles (AgNPs) against cervical cancer

Bachelor’s Degree in Biology
20/01/2014 – 30/12/2020, Al-Neelain University, Khartoum, Sudan
Final Grade: 76.94%
Thesis: Phytochemical screening and antimicrobial activity of methanol & n-Hexane extract of roots S.Lappa

πŸ“œ Training and Certifications

  • Computer Science Training Course
    02/28/2010 – 31/05/2010, Intercontinental Institute for Computer Science, Omdurman, Sudan
  • Molecular Biology Techniques Practical Training
    05/08/2017 – 12/08/2017, National Center for Research, Khartoum, Sudan
  • Quality Control Practical Training
    02/03/2019 – 16/03/2019, Sudanese Standards and Metrology Organization, Khartoum, Sudan
  • Community-Based Health First Aid Training
    18/10/2020 – 18/11/2020, Sudanese Red Crescent, Khartoum, Sudan
  • Introduction to Bioinformatics Training (IBT)
    05/07/2021 – 05/11/2021, Pan African Bioinformatics Network For H3Africa
  • Online Courses in Cancer Biology and Management
    2020-2021, Johns Hopkins University and other institutions

πŸ† Awards and Honors

  • Scientific Cultural Week – Al-Neelain University
    02/07/2018 – Second place for cancer topic in the Faculty of Science and Technology.
  • Pan Africa Scholarship
    04/2022 – Full scholarship for a master’s degree at PAUSTI.
  • 3rd Runner-Up Best Poster Presentation
    06/12/2023 – 08/12/2023, 1st Cancer Research Symposium – Poster on “Anticancer potential of silver nanoparticles biosynthesized using Catharanthus roseus leaves extract on cervical cancer.”

πŸ”¬ Publications and Research Projects

  • Phytochemical Screening and Antimicrobial Activity of Methanol and n-Hexane Roots Extract of Saussurea Lappa 30/09/2020 – 31/10/2020
  • Antiproliferative and Anti-metastatic Activities of Catharanthus roseus-based Silver Nanoparticles (AgNPs) Against Cervical Cancer 01/04/2023 – Current

🌐 Networks and Memberships

  • American Association for Cancer Research (Associate Member)
    02/08/2023 – 31/12/2023
  • Biochemistry and Biotechnology Professionals Society of Kenya (BBPSK)
    01/06/2023 – 01/06/2024
  • Young African Leaders Initiative Network (YALI)
    06/09/2021 – Current

🌍 Volunteering

Volunteer, Brothers in Humanity Initiative
24/10/2019 – Current, Khartoum, Sudan

  • Participated in blood donation campaigns and health awareness activities focused on childhood cancer.

πŸ› οΈ Digital Skills

  • Microsoft Office Suite, R Programming, SPSS, GraphPad Prism, OrginPro, Bioinformatics Software (BIOEDIT, DNAsp, TSC, GENE BANK, STRUCTURE), Molecular Docking, Linux (Terminal Commands, Bash/Shell)

🌟 Hobbies and Interests

  • Volunteering, Website Design, Teamwork, Leadership, Flexibility

πŸ“‡ References

Dr. Caroline Ngugi
Senior Lecturer and Chairperson, Department of Medical Microbiology, JKUAT
πŸ“§ cwngugi@jkuat.ac.ke | πŸ“ž (+254) 72256790

Prof. Hiba Khalil
Professor of Hematology and Stem Cell Technology, Director, Al-Neelain Stem Cell Center
πŸ“§ hibabadr@gmail.com | πŸ“ž (+249) 123012356

Dr. Seedahmed A. Mohammed
Assistant Professor, Al-Neelain University
πŸ“§ seedahmed@neelain.edu.sd | πŸ“ž (+249) 904030042

Dr. Faisal Koua
Scientist, FS-CFEL-1 Biomedical Research with X-Rays, Deutsches Elektronen-Synchrotron
πŸ“§ fkoua@asu.edu | πŸ“ž (+49) 4089986372

Dr. Atif Idrees
Head of the Department of Biology and Biotechnology, Professor of Immunology, Al-Neelain University
πŸ“§ atifokaz@gmail.com | πŸ“ž (+249) 123664711

πŸ“ŠπŸ”¬Notable Publication:

Title: Anticancer potential of silver nanoparticles biosynthesized using Catharanthus roseus leaves extract on cervical (HeLa229) cancer cell line

Authors: Hadil Suliman Hussein Adam, [other authors if applicable]

Journal: Scientific African

Year: 2024

Prof Dr. ClausGarbe – Oncology Management and Prevention – Lifetime achievement Award

Prof Dr. ClausGarbe - Oncology Management and Prevention - Lifetime achievement Award

University of Tuebingen - Germany

AUTHOR PROFILE

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Professor Claus Garbe embarked on his academic journey by obtaining his MD from the Free University of Berlin in 1983. Following this, he pursued board certification in Dermatology and Venereology in 1987. His early academic pursuits laid the foundation for his subsequent groundbreaking work in dermatology and oncology.

PROFESSIONAL ENDEAVORS:

In 1990, Professor Garbe achieved his habilitation, akin to a PhD equivalent, with a focus on the biology of melanoma cells. This marked a significant milestone in his academic career, demonstrating his commitment to advancing the understanding of melanoma, a deadly form of skin cancer. In 1995, he transitioned to Eberhard Karls University, Tuebingen, where he assumed the role of University Professor of Dermatology and Head of the Division of Dermatooncology. This move expanded his scope of influence and provided a platform for furthering his research and clinical endeavors.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY MANAGEMENT AND PREVENTION

Professor Garbe's contributions to the field of dermatology and oncology are extensive and profound. His principal research interests encompass the biology and genetics of melanoma and keratinocyte skin cancers, therapeutic trials in skin diseases, epidemiologic studies, and dermato-histopathology. Through his pioneering research, he has elucidated crucial mechanisms underlying skin cancer development and progression, paving the way for innovative therapeutic approaches and preventive strategies.

IMPACT AND INFLUENCE:

Professor Garbe's impact on the field of dermatologic oncology is unparalleled. His leadership roles in numerous multicenter clinical trials since 1989 have facilitated the translation of research findings into clinical practice, ultimately improving patient outcomes. Moreover, his presidency of the European Association of Dermatologic Oncology (EADO) underscores his influence on a global scale, driving collaboration and innovation in the fight against skin cancer.

ACADEMIC CITATIONS:

With over 800 articles and 17 textbooks to his name, Professor Garbe's scholarly output is prolific. His impressive H-index of 116 points reflects the significant impact of his work within the scientific community. His research findings have been cited extensively, highlighting their relevance and contribution to advancing knowledge in dermatology and oncology.

LEGACY AND FUTURE CONTRIBUTIONS:

Professor Garbe's legacy is characterized by his unwavering dedication to advancing the field of dermatologic oncology. His contributions have not only expanded our understanding of skin cancer but have also shaped clinical practice and guidelines. As he continues to spearhead research efforts and mentor the next generation of scientists and clinicians, his legacy is poised to endure, leaving an indelible mark on the field for years to come.

NOTABLE PUBLICATIONS

Sentinel lymph node biopsy is unreliable in predicting melanoma mortality for both younger and older patients. 2024 (2)

Sentinel lymph node biopsy for lentigo maligna melanoma under local anaesthesia. 2024 (3)

Epidemiology of Keratinocyte Skin Cancer with a Focus on Cutaneous Squamous Cell Carcinoma. 2024 (1)

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. 2023 (6)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. 2023 (2)

Prof Dr. Nives PeΔ‡ina-Ε laus – Cancer Genetics – Best Researcher Award

Prof Dr. Nives Pećina-Šlaus - Cancer Genetics - Best Researcher Award

Department of Biology School of Medicine University of Zagreb - Croatia

AUTHOR PROFILEΒ 

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Nives Pecina-Slaus embarked on her academic journey at the University of Zagreb, where she earned her Bachelor's and Master's degrees in Biology in 1990 and 1992, respectively. Her scholarly pursuits culminated in a Ph.D. in the field of molecular oncology from the Medical School at the University of Zagreb in 1998. During her education, she underwent training at prestigious institutions including the Cold Spring Harbor Laboratory in New York and Georgetown University in Washington DC, USA.

PROFESSIONAL ENDEAVORS

Pecina-Slaus's professional career is distinguished by her role as a tenured professor at the Department of Biology and Head of the Laboratory of Neuro-oncology at the Croatian Institute for Brain Research within the School of Medicine at the University of Zagreb. She has served as the principal investigator on seven scientific projects, demonstrating her leadership in the field. Moreover, her research has yielded significant contributions, with over 100 publications to her credit, including scientific papers, book chapters, and a book. Her primary research interests encompass cancer genetics, the Wnt signaling pathway, epithelial to mesenchymal transition, brain tumorigenesis, tumor suppressor genes, and oncogenes.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Pecina-Slaus's work has contributed extensively to our understanding of neuro-oncology and related fields. Her research has shed light on crucial mechanisms underlying cancer development and progression, particularly in the context of brain tumors. Through her numerous publications, she has disseminated valuable insights into cancer genetics, signaling pathways, and tumor microenvironment dynamics. Her expertise extends to mentorship, where she has guided numerous students in their theses.

IMPACT AND INFLUENCE

Pecina-Slaus's contributions have garnered widespread recognition in the scientific community, as evidenced by her invitations to speak at 25 meetings. Furthermore, her work has had a substantial impact on the academic community, as reflected in her impressive citation metrics. With over 2600 citations on Google Scholar and notable indices on Scopus and Web of Science, she has established herself as a respected authority in her field.

ACADEMIC LEGACY AND FUTURE CONTRIBUTIONS

Pecina-Slaus's legacy is marked by her prolific research output, mentorship of students, and editorial roles in esteemed scientific journals. Her dedication to advancing knowledge in neuro-oncology and related disciplines has earned her numerous awards and accolades, including recognition from the Croatian Medical Association and the Academy of Medical Sciences. Moving forward, she is poised to continue making significant contributions to the field through her research, teaching, and editorial activities, further solidifying her position as a leader in neuro-oncology research.

NOTABLE PUBLICATIONS

Glioma Stem Cellsβ€”Features for New Therapy Design. 2024

Genetics in ophthalmology: molecular blueprints of retinoblastoma. 2023 (3)

Wnt Signaling Inhibitors and Their Promising Role in Tumor Treatment. 2023 (6)

Different Approaches to Study Molecular Blueprint and Biological Behavior of Brain Tumors: Editorial to the Special Issue β€œAdvances in Molecular Genetics of Brain Tumors”. 2023

Bilateral Meningioma: A Case Report and Review of the Literature. 2022 (2)

 

 

Prof Dr. Zsuzsanna Suba – Cancer Genetics – Distinguished Cancer Treatment Innovation Award

Prof Dr. Zsuzsanna Suba - Cancer Genetics - Distinguished Cancer Treatment Innovation Award

National Institute of Oncology, Budapest - Hungary

AUTHOR PROFILE

Orcid

EARLY ACADEMIC PURSUITS

Prof. Dr. Zsuzsanna Suba began her academic journey at Semmelweis University in Budapest, where she earned both MD and PhD degrees. During this time, she also obtained postdoctoral board certification in pathology, laying the foundation for her expertise in cancer research.

PROFESSIONAL ENDEAVORS

After completing her postdoctoral certification, Suba delved into cancer research, initially focusing on the effects of chemotherapeutic agents on cell cultures and experimental animals. Later, she expanded her expertise by gaining scientific graduations in oral pathology and habilitation at the Institute of Oral and Maxillofacial Surgery, Semmelweis University, as well as a certification in oral pathology from the University of Sheffield.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Suba's research has been multifaceted, covering various aspects of cancer development and therapy response. She led a working group that investigated the osseointegration of biomaterials in oral and periodontal tissues and explored metabolic and hormonal aspects of oral cancer. Notably, her research identified insulin resistance and estrogen deficiency as risk factors for oral cancer.At the National Institute of Oncology in Budapest, Suba delved into the correlations among hormonal imbalance, metabolic disorders, and genomic instability in female breast cancer patients.

IMPACT AND INFLUENCE

Suba's work has significantly contributed to our understanding of cancer development and treatment response, particularly in oral and breast cancer. Her identification of novel risk factors and exploration of hormonal and metabolic influences have informed both clinical practice and further research in the field.

ACADEMIC CITATIONS

Suba's contributions to cancer research have garnered recognition and citations within the academic community, solidifying her reputation as an expert in clinical cancer genetics and pathology.

LEGACY AND FUTURE CONTRIBUTIONS

As a professor emeritus, Suba continues to shape the future of cancer research, advocating for new strategies that prioritize DNA stabilization in cancer cases. Her emphasis on supportive cancer care underscores the importance of innovative approaches to enhance patient outcomes and quality of life.

NOTABLE PUBLICATIONS

DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care. 2024

Compensatory Estrogen Signal Is Capable of DNA Repair in Antiestrogen-Responsive Cancer Cells via Activating Mutations. 2020 (7)

 

Dr. Francesco Raspagliesi – Gynecologic Oncology – Best Researcher Award

Dr. Francesco Raspagliesi - Gynecologic Oncology - Best Researcher Award

Fondazione IRCCS Istituto nazionale Tumori di Milano - Italy Β 

Author Profile

Scopus

EARLY ACADEMIC PURSUITS

Francesco Raspagliesi began his academic journey with a Degree in Medicine and Surgery from the University of Catania, Italy, which he completed on March 7, 1981. Following this foundational education, he obtained qualifications to practice medicine in 1981 and specialized in Obstetrics and Gynecology from the University of Catania in 1985 and 1988. These early academic pursuits laid the groundwork for his future professional endeavors in the field of gynecologic oncology.

PROFESSIONAL ENDEAVORS

From 1985 to 1992, Raspagliesi served as a Research Fellow at the Fondazione IRCCS Istituto Nazionale Tumori di Milano. He continued his professional growth at the same institution, becoming a Dirigente Medico di 1Β° Livello from 1992 to 1999 and advancing to Dirigente Medico di 2Β° Livello Gynecologic Oncology Unit Director from 1999 to 2019. His long-standing association with the Fondazione IRCCS Istituto Nazionale Tumori di Milano demonstrates his commitment and dedication to the field of gynecologic oncology and patient care.

CONTRIBUTIONS AND RESEARCH FOCUS ON GYNECOLOGIC ONCOLOGY

Throughout his career, Raspagliesi has made significant contributions to the field of Obstetrics and Gynecology. His research and clinical work have focused on gynecologic oncology, particularly in the treatment and management of gynecologic cancers. His expertise and leadership as the Gynecologic Oncology Unit Director have contributed to advancements in the diagnosis, treatment, and care of patients with gynecologic cancers.

IMPACT AND INFLUENCE

As a respected figure in the field of gynecologic oncology, Raspagliesi's work has had a profound impact on patient care, research, and education. His leadership roles and contributions to research have helped shape the way gynecologic cancers are treated and managed, influencing clinical practice and improving patient outcomes.

LEGACY AND FUTURE CONTRIBUTIONS

Francesco Raspagliesi's legacy in the field of Obstetrics and Gynecology is characterized by his dedication to patient care, leadership in gynecologic oncology, and contributions to research and education. His continued commitment to advancing the field through research, mentorship, and clinical practice ensures that his influence will be felt by future generations of gynecologic oncologists.

NOTABLE PUBLICATIONS

Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.Β  2024

Sentinel node mapping in high-intermediate and high-risk endometrial cancer: Analysis of 5-year oncologic outcomes. 2024

Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs.Β  2024

Impact of Cold Ischemia on the Stability ofΒ 1H-MRS-Detected Metabolic Profiles of Ovarian Cancer Specimens. 2024

Concurrent Endometrial Cancer in Women with Atypical Endometrial Hyperplasia: What Is the Predictive Value of Patient Characteristics? (2) 2024

 

 

Prof. Apostolos Zaravinos – Cancer Genetics – Excellence in Research

Prof. Apostolos Zaravinos - Cancer Genetics - Excellence in Research

European University Cyprus - Cyprus

Author Profile

Google Scholar

Orcid

Scopus

EARLY ACADEMIC PURSUITS

Dr. Apostolos Zaravinos began his academic journey with a B.Sc. in Molecular Biology from the Department of Biology at the University of Crete in 2004. He further pursued his passion for medicine by obtaining his Ph.D. in Medicine from the Medical School of the same university in 2008. These foundational academic pursuits laid the groundwork for his subsequent research and professional endeavors in the field of cancer genetics and molecular biology.

PROFESSIONAL ENDEAVORS

After completing his Ph.D., Dr. Zaravinos embarked on a series of professional roles that enriched his expertise and contributed to the scientific community. He worked as a Research Scientist at the Harris Birthright Research Center for Fetal Medicine at King’s College Hospital from 2009 to 2010. Subsequently, he performed postdoctoral research in Cancer Genetics at the Molecular Medicine Research Center of the University of Cyprus from 2011 to 2013. He further honed his skills in Immunogenetics and Cancer Genetics during his postdoctoral training at the Department of Laboratory Medicine of the Karolinska Institute from 2013 to 2015.In 2015, Dr. Zaravinos was appointed as an Assistant Professor of Cancer Genetics at the European University Cyprus. He was promoted to the rank of Associate Professor in 2019. He also served as an Associate Professor of Genetics at the Department of Basic Medical Science, College of Medicine (CMED) at Qatar University from 2020 to 2021. These academic positions allowed him to mentor students, lead research projects, and contribute to the advancement of cancer genetics and immunogenetics.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Dr. Zaravinos' research contributions are significant and multifaceted. His primary research aim is to achieve an advanced understanding of carcinogenesis by investigating interactions between genes. He is particularly interested in Cancer Immunogenetics and aims to elucidate how the tumor microenvironment relates to different aspects of tumor biology. His research has focused on examining the immune landscape of inflamed tumors, including colorectal cancer and skin melanoma, using next-generation sequencing approaches.

IMPACT AND INFLUENCE

Dr. Zaravinos has made a substantial impact on the field of cancer genetics and immunogenetics. He has authored over 125 original research articles and 7 book chapters, demonstrating his prolific research output. His work has been cited over 3,600 times, with an h-index of 35, as documented on Scopus. His research findings have contributed to the scientific community's understanding of carcinogenesis, tumor immunology, and the tumor microenvironment.

ACADEMIC CITES

Dr. Zaravinos' research has garnered significant attention and recognition in the scientific community, as evidenced by his high citation count and h-index. His publications have been cited over 3,600 times, highlighting the impact and relevance of his research in the field of cancer genetics and immunogenetics.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Zaravinos' legacy in the field of cancer genetics and immunogenetics is characterized by his groundbreaking research, mentorship, and contributions to scientific literature. His work has paved the way for future research endeavors aimed at understanding carcinogenesis, tumor immunology, and the tumor microenvironment. As a dedicated researcher and educator, Dr. Zaravinos continues to inspire and influence the next generation of scientists, leaving a lasting impact on the field of cancer genetics and molecular biology. His future contributions are eagerly anticipated as he continues to explore new avenues in cancer research and mentor emerging scientists in the field.

NOTABLE PUBLICATIONS

Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1. 2024

Peptide absent sequences emerging in human cancers. 2024

Immune Cytolytic Activity and Strategies for Therapeutic Treatment. 2024

Strand asymmetries across genomic processes. 2023

Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies. 2023 (3)